Market Cap 34.39M
Revenue (ttm) 13.90M
Net Income (ttm) 10,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.07%
Debt to Equity Ratio 0.44
Volume 5,000
Avg Vol 70,536
Day's Range N/A - N/A
Shares Out 528.21M
Stochastic %K 40%
Beta 0.94
Analysts Strong Buy
Price Target N/A

Company Profile

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotop...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 208 524 5300
Address:
4137 Commerce Circle, Idaho Falls, United States
TILResearch
TILResearch Mar. 20 at 5:58 PM
$INIS Last post about this. I wrote my thoughts in a new post that is more complete than these snippets. TLDR: it might still be a good investment, but there are a lot of issues with the balance sheet that need to be addressed: https://www.theinvestmentlog.com/posts/inis/2026-03-19 I think this company will end up being owned by the board unless they find a new entity to acquire DUF6. It should at least help that people know it's for sale now
0 · Reply
TILResearch
TILResearch Mar. 17 at 4:19 PM
$INIS I guess the spin is that now that they aren't selling their DUF6 asset to American Fuel, they can sell it for more money? I hope this works out, but I'm skeptical. We'll see, the market seems to like this news
0 · Reply
TILResearch
TILResearch Mar. 16 at 2:45 PM
$INIS I have also had troubles getting any sort of response from investor relations. A company like this really needs to learn to communicate better with shareholders
0 · Reply
TILResearch
TILResearch Mar. 16 at 2:45 PM
$INIS terminated the asset sale of DUF6. This seems like a much less interesting company when they have this anchor tied to them. Hopefully they can find another buyer now that they have somewhat proven out the process. My concern is that the company is going to wipe out equity holders and end up with the debt holders taking over. Would have been great to get this cash influx so they could clean up the balance sheet
0 · Reply
LifesGood
LifesGood Mar. 6 at 1:50 PM
$INIS My Overall OpinionINIS (Radnostix) shows some positive momentum: revenue growth, margin expansion, and a pivot to high-potential areas like theranostics and medical devices, which align with aging populations and advances in nuclear medicine. The asset sale could inject significant cash (~6x current cash reserves), potentially funding R&D or debt reduction, and the name change signals a clearer healthcare focus. If executed well, this could position it for profitability in a niche market with barriers to entry (e.g., regulatory expertise).However, it's a highly speculative investment. The company is tiny, with razor-thin profits, heavy debt relative to equity, and a history of losses that could recur if supplies falter or regulations tighten. Liquidity is precarious, and the registration revocation adds red flags—reduced transparency could mean hidden problems or just administrative fallout from the rebrand. At $0.09/share, it's cheap, but volatility is high, trading volume low,
1 · Reply
TILResearch
TILResearch Mar. 4 at 9:34 PM
$INIS I'm surprised there hasn't been any news on the DUF6 asset disposal. I am really hoping they can get it buttoned up in March. What will come next for Radnostix?
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 21 at 3:03 PM
$INIS Brilliant piece that captures INIS's situation perfectly. So if you want to update your understanding of INIS or get to know INIS better, this is essential reading. https://everyticker.com/quote/INIS/analysis/international-isotopes-radioactive-moats-meet-operational-meltdown-nasdaq-inis
0 · Reply
LifesGood
LifesGood Nov. 17 at 3:00 PM
0 · Reply
d_risk
d_risk Nov. 14 at 2:42 PM
$INIS - INTERNATIONAL ISOTOPES INC - 10Q - Updated Risk Factors INIS flags new risks from volatile raw material and energy costs, potential distributor instability, reliance on overseas isotope suppliers vulnerable to geopolitical shifts, ongoing efforts to secure critical isotopes via a new joint venture, and continued supply chain disruptions threatening sales and revenue. #IsotopeIndustry #JointVenture #EnergyCostVolatility #GeopoliticalRisk #SupplyChainRisk 🟢 Added 🟠 Removed https://d-risk.ai/INIS/10-Q/2025-11-14
0 · Reply
LifesGood
LifesGood Oct. 30 at 12:59 PM
0 · Reply
Latest News on INIS
No data available.
TILResearch
TILResearch Mar. 20 at 5:58 PM
$INIS Last post about this. I wrote my thoughts in a new post that is more complete than these snippets. TLDR: it might still be a good investment, but there are a lot of issues with the balance sheet that need to be addressed: https://www.theinvestmentlog.com/posts/inis/2026-03-19 I think this company will end up being owned by the board unless they find a new entity to acquire DUF6. It should at least help that people know it's for sale now
0 · Reply
TILResearch
TILResearch Mar. 17 at 4:19 PM
$INIS I guess the spin is that now that they aren't selling their DUF6 asset to American Fuel, they can sell it for more money? I hope this works out, but I'm skeptical. We'll see, the market seems to like this news
0 · Reply
TILResearch
TILResearch Mar. 16 at 2:45 PM
$INIS I have also had troubles getting any sort of response from investor relations. A company like this really needs to learn to communicate better with shareholders
0 · Reply
TILResearch
TILResearch Mar. 16 at 2:45 PM
$INIS terminated the asset sale of DUF6. This seems like a much less interesting company when they have this anchor tied to them. Hopefully they can find another buyer now that they have somewhat proven out the process. My concern is that the company is going to wipe out equity holders and end up with the debt holders taking over. Would have been great to get this cash influx so they could clean up the balance sheet
0 · Reply
LifesGood
LifesGood Mar. 6 at 1:50 PM
$INIS My Overall OpinionINIS (Radnostix) shows some positive momentum: revenue growth, margin expansion, and a pivot to high-potential areas like theranostics and medical devices, which align with aging populations and advances in nuclear medicine. The asset sale could inject significant cash (~6x current cash reserves), potentially funding R&D or debt reduction, and the name change signals a clearer healthcare focus. If executed well, this could position it for profitability in a niche market with barriers to entry (e.g., regulatory expertise).However, it's a highly speculative investment. The company is tiny, with razor-thin profits, heavy debt relative to equity, and a history of losses that could recur if supplies falter or regulations tighten. Liquidity is precarious, and the registration revocation adds red flags—reduced transparency could mean hidden problems or just administrative fallout from the rebrand. At $0.09/share, it's cheap, but volatility is high, trading volume low,
1 · Reply
TILResearch
TILResearch Mar. 4 at 9:34 PM
$INIS I'm surprised there hasn't been any news on the DUF6 asset disposal. I am really hoping they can get it buttoned up in March. What will come next for Radnostix?
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 21 at 3:03 PM
$INIS Brilliant piece that captures INIS's situation perfectly. So if you want to update your understanding of INIS or get to know INIS better, this is essential reading. https://everyticker.com/quote/INIS/analysis/international-isotopes-radioactive-moats-meet-operational-meltdown-nasdaq-inis
0 · Reply
LifesGood
LifesGood Nov. 17 at 3:00 PM
0 · Reply
d_risk
d_risk Nov. 14 at 2:42 PM
$INIS - INTERNATIONAL ISOTOPES INC - 10Q - Updated Risk Factors INIS flags new risks from volatile raw material and energy costs, potential distributor instability, reliance on overseas isotope suppliers vulnerable to geopolitical shifts, ongoing efforts to secure critical isotopes via a new joint venture, and continued supply chain disruptions threatening sales and revenue. #IsotopeIndustry #JointVenture #EnergyCostVolatility #GeopoliticalRisk #SupplyChainRisk 🟢 Added 🟠 Removed https://d-risk.ai/INIS/10-Q/2025-11-14
0 · Reply
LifesGood
LifesGood Oct. 30 at 12:59 PM
0 · Reply
AlphaTuna
AlphaTuna Oct. 28 at 12:09 AM
Lowest Volume Rated General Stocks Per 10/27/2025’s Close: 1 – $INIS 2 – $AVCNF 3 – $ACLLF 4 – $VRBFF 5 – $GRCAF 6 – $PFAI 7 – $LODFF 8 – $RGLSF 9 – $NCT 10 – $UOKA https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-10-27-2025/
1 · Reply
LifesGood
LifesGood Sep. 26 at 12:11 AM
0 · Reply
LifesGood
LifesGood Sep. 17 at 8:55 PM
$INIS Latest News and Strategic Developments Q2 2025 Financial Results: The most recent news, as of August 13, 2025, is the release of its Q2 2025 Form 10-Q report. The report highlighted positive sales growth in specific segments and a reduction in net loss, which is an encouraging sign. Expansion: The company has been actively expanding its operations. It has leased a second facility and is preparing to launch new medical devices in early 2026, which are products from its acquisition of the AMICI, Inc. product line. Insider Activity: There has been a significant amount of insider buying over the last year, which could be interpreted as a sign of confidence from management and key stakeholders.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 2:36 PM
$INIS Brilliant piece that captures INIS's situation perfectly. So if you want to update your understanding of INIS or get to know INIS better, this is essential reading. https://beyondspx.com/quote/INIS/international-isotopes-unearthing-niche-dominance-in-radiopharmaceuticals-and-nuclear-services-inis#analysis
0 · Reply
LifesGood
LifesGood Aug. 22 at 10:30 PM
0 · Reply
LifesGood
LifesGood Aug. 13 at 3:15 PM
$INIS IDAHO FALLS, Idaho , Aug. 13, 2025 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or " INIS") is pleased to announce its financial results for the second quarter and six months ended June 30, 2025 . Revenue from the sale of product for the second quarter of 2025 was $3,655,320 , an increase of $486,087 or 15.3%, compared to the same period in the prior year, and for the six months ended June 30, 2025 was $6,894,220 , an increase of $820,529 or 13.5% from the same period in the prior year. Net loss for the second quarter of 2025 improved to $160,785 from a loss of $233,445 in the same period last year, a 27% increase, and for the first six months of 2025 improved to $273,479 , a 29.4% improvement from the same period in the prior year. Non-GAAP EBITDA(1) increased to $1,199 in the second quarter of 2025, an increase of $85,202 , and non-GAAP EBITDA(1) for the first six months of 2025 improved to $51,569 , a 157% improvement from the
0 · Reply
vu_jade
vu_jade Jul. 22 at 2:24 PM
$INIS what’s the next penny to make 200% .. I buy before momentum? Thanks
0 · Reply
Bok987
Bok987 Jul. 20 at 12:00 PM
$INIS I find it concerning that there is no executive profile on web site. On Linkedin, it's seems most are hidden. Why is that?
0 · Reply
vu_jade
vu_jade Jun. 24 at 9:10 PM
$INIS doubled my money .. sold a bunch
0 · Reply
vu_jade
vu_jade Jun. 24 at 7:18 PM
$INIS there’s a buyer here .. up listing?
0 · Reply